Sandoz prepares to use untested US biosimilar pathway
This article was originally published in SRA
Executive Summary
Sandoz is preparing US approval filings for its biosimilar versions of Amgen's Neupogen (filgrastim) and Neulasta (pegfilgrastim)1. The Swiss company already has a strong presence in the EU biosimilars segment, and now looks set to be among the first to use the untested US biosimilars pathway.